Brokerages Set Surgery Partners, Inc. (NASDAQ:SGRY) PT at $43.63

Shares of Surgery Partners, Inc. (NASDAQ:SGRY) have received a consensus rating of “Moderate Buy” from the eight research firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $43.63.

A number of research analysts recently issued reports on the company. Citigroup lowered their target price on Surgery Partners from $43.00 to $42.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Cantor Fitzgerald reissued an “overweight” rating and set a $43.00 target price on shares of Surgery Partners in a research note on Wednesday, April 10th. Benchmark reiterated a “buy” rating and set a $50.00 price objective on shares of Surgery Partners in a research report on Wednesday, May 1st. Barclays began coverage on shares of Surgery Partners in a research report on Wednesday, March 6th. They issued an “equal weight” rating and a $35.00 target price on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $49.00 price objective on shares of Surgery Partners in a report on Thursday, February 29th.

Surgery Partners Price Performance

Shares of SGRY opened at $24.53 on Friday. Surgery Partners has a one year low of $22.05 and a one year high of $45.79. The stock’s fifty day moving average is $27.63 and its 200-day moving average is $29.79. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.57 and a current ratio of 1.71. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of -245.30, a price-to-earnings-growth ratio of 2.24 and a beta of 2.75.

Surgery Partners (NASDAQ:SGRY) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $735.40 million during the quarter, compared to analyst estimates of $741.93 million. Surgery Partners had a negative net margin of 0.43% and a positive return on equity of 3.65%. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.22 EPS. Equities analysts anticipate that Surgery Partners will post 0.78 EPS for the current year.

Insider Buying and Selling at Surgery Partners

In other news, CEO Jason Eric Evans sold 5,780 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $35.08, for a total value of $202,762.40. Following the completion of the sale, the chief executive officer now directly owns 419,118 shares in the company, valued at $14,702,659.44. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, insider Bradley R. Owens sold 1,040 shares of Surgery Partners stock in a transaction on Monday, February 12th. The stock was sold at an average price of $35.22, for a total value of $36,628.80. Following the completion of the sale, the insider now directly owns 73,149 shares of the company’s stock, valued at approximately $2,576,307.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jason Eric Evans sold 5,780 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $35.08, for a total value of $202,762.40. Following the transaction, the chief executive officer now directly owns 419,118 shares in the company, valued at approximately $14,702,659.44. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,831 shares of company stock worth $482,609. 2.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Mesirow Institutional Investment Management Inc. boosted its stake in Surgery Partners by 12.4% during the 4th quarter. Mesirow Institutional Investment Management Inc. now owns 3,388 shares of the company’s stock worth $108,000 after acquiring an additional 373 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Surgery Partners by 7.6% in the 3rd quarter. Amalgamated Bank now owns 9,948 shares of the company’s stock valued at $291,000 after buying an additional 701 shares during the period. Raymond James & Associates raised its holdings in shares of Surgery Partners by 1.2% in the third quarter. Raymond James & Associates now owns 61,188 shares of the company’s stock valued at $1,790,000 after purchasing an additional 736 shares during the last quarter. Natixis Advisors L.P. lifted its position in Surgery Partners by 8.6% during the 4th quarter. Natixis Advisors L.P. now owns 11,735 shares of the company’s stock worth $375,000 after buying an additional 934 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Surgery Partners by 69.7% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,945 shares of the company’s stock worth $86,000 after buying an additional 1,210 shares during the last quarter.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.